US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.

The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

A contract for the running of a youth alcohol and other drug rehabilitation centre has been awarded to a Far North ...

"So there is an unmet need still in the treatment of schizophrenia, particularly in patients who may show response to the ...

Tammy Swierczynski (Oneida/Menominee), who helped to organize a talking circle for the event, said the story of the ...

The facility will offer inpatient and outpatient services, including long-term stays, detox, individual and group therapy.

A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...